Revvity, Inc. (RVTY)

NYSE: RVTY · IEX Real-Time Price · USD
108.65
-2.07 (-1.87%)
Jun 14, 2024, 4:00 PM EDT - Market closed
-1.87%
Market Cap 13.41B
Revenue (ttm) 2.73B
Net Income (ttm) 149.63M
Shares Out 123.39M
EPS (ttm) 1.22
PE Ratio 89.06
Forward PE 22.27
Dividend $0.28 (0.26%)
Ex-Dividend Date Jul 19, 2024
Volume 1,058,608
Open 110.01
Previous Close 110.72
Day's Range 107.62 - 110.70
52-Week Range 79.50 - 131.96
Beta 1.08
Analysts Buy
Price Target 118.17 (+8.76%)
Earnings Date Jul 30, 2024

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its pro... [Read more]

Sector Healthcare
Founded 1937
Employees 11,500
Stock Exchange NYSE
Ticker Symbol RVTY
Full Company Profile

Financial Performance

In 2023, Revvity's revenue was $2.75 billion, a decrease of -16.95% compared to the previous year's $3.31 billion. Earnings were $693.09 million, an increase of 21.77%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $118.17, which is an increase of 8.76% from the latest price.

Price Target
$118.17
(8.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Revvity to Present at Goldman Sachs Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL. Prahlad Si...

18 days ago - Business Wire

Revvity beats quarterly estimates on demand for diagnostic equipment

Revvity on Monday beat Wall Street estimates for its quarterly profit and revenue, helped by better-than-expected demand for equipment in its diagnostics unit.

6 weeks ago - Reuters

Revvity Announces Financial Results for the First Quarter of 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as comp...

6 weeks ago - Business Wire

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2...

7 weeks ago - Business Wire

Revvity to Present at BofA Securities 2024 Health Care Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice Presi...

7 weeks ago - Business Wire

Revvity Unveils a New Era of Automated Tuberculosis Testing

WALTHAM, Mass.--(BUSINESS WIRE)-- #TB--Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 plat...

7 weeks ago - Business Wire

Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM, a software solution designed to...

2 months ago - Business Wire

Revvity To Hold Earnings Call on Monday, April 29, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company w...

2 months ago - Business Wire

Preliminary Injunction Granted to Enforce Revvity's Rights and Cloud Software Group's Obligations Related to Spotfire Software

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply ...

2 months ago - Business Wire

Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive r...

3 months ago - Business Wire

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, th...

3 months ago - Business Wire

Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagen...

3 months ago - Business Wire

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sci...

4 months ago - Business Wire

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-...

4 months ago - Business Wire

Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024

WALTHAM, Mass.--(BUSINESS WIRE)-- #biotech--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 t...

4 months ago - Business Wire

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAA...

4 months ago - Business Wire

Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am...

5 months ago - Business Wire

Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2...

5 months ago - Business Wire

Revvity to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA. Preside...

6 months ago - Business Wire

PerkinElmer Acquires Covaris to Create an Innovation-Led, Global Life-Sciences and Diagnostics Platform

SHELTON, Conn.--(BUSINESS WIRE)--PerkinElmer, a leading global analytical services and solutions provider, today announced that it has acquired Covaris, a leading developer of solutions to empower lif...

6 months ago - Business Wire

Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt mo...

7 months ago - Business Wire

Revvity to Present at Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 9:10 a.m. ET in Miami, FL. President and ...

7 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - RVTY

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revvity, Inc. ("Revvity" or the "Company") (NYSE: RVTY).  Such investors are advised to contact ...

8 months ago - PRNewsWire

Revvity Stock Tumbles 18% as Demand From Pharma and Biotech Customers Falls

Revvity posts third-quarter earnings of $1.18 a share, 1 cent below estimates. Revenue of $670.7 million also came in below forecasts.

8 months ago - Barrons

Revvity's stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlook

Shares of Revvity Inc. RVTY, -1.09% tumbled 14.2% toward a 3 1/2-year low Monday, enough to pace the S&P 500's SPX, +0.72% premarket decliners, after the health sciences company missed third-quarter e...

8 months ago - Market Watch